gamma-Eudesmol is a sesquiterpene alcohol found in eudesmol-rich wood, root, and leaf oils including blue cypress, hinoki leaf-twig oil, and carrot seed oil in the AromaForge archive. Its evidence base is stronger than many minor sesquiterpenes because public sources support its identity, repeated occurrence, and several constituent-level preclinical studies. Those studies remain experimental and cell-focused, so AromaForge should position gamma-eudesmol as a compositional marker with notable early-stage bioactivity signals rather than as an established human therapeutic ingredient.
Chemical identity and composition
PubChem REST data identifies gamma-Eudesmol as CID 6432005 with formula C15H26O and the IUPAC name 2-[(2R,4aR)-4a,8-dimethyl-2,3,4,5,6,7-hexahydro-1H-naphthalen-2-yl]propan-2-ol. PubChem synonym data supports CAS 1209-71-8 and common names including machilol, uncineol, and selinenol. In the local archive, public oil records place gamma-eudesmol among principal constituents of blue cypress and hinoki leaf-twig oil, with smaller but still explicit occurrence in carrot seed oil.
Aroma and practical use
- Use the recorded woody, sweet, balsamic, waxy descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
major occurrence in blue cypress
A directly readable blue cypress monograph lists gamma-eudesmol at 9.14% among the principal constituents, supporting its role as a major marker in Callitris intratropica wood oil.
Measured: relative abundance
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
hepg2 apoptosis and cytotoxicity
A Europe PMC abstract reports gamma-eudesmol IC50 values ranging from 8.86 +/- 1.27 to 15.15 +/- 1.06 microg/mL across tested tumor cell lines and describes mitochondrial membrane-potential loss plus caspase-3 activation in HepG2 cells.
Measured: cytotoxicity and apoptosis-associated markers
This experimental finding does not establish benefit, dose or safety in people using this blend.
guatteria friesiana component level antitumor context
A Europe PMC abstract on Guatteria friesiana leaf oil states that isolated gamma-eudesmol showed in vitro cytotoxicity with reported IC50 values ranging from 7.1 to 20.6 microg/mL across tested tumor cell lines, while the parent oil showed antitumor activity in mice.
Measured: tumor-cell cytotoxicity
This experimental finding does not establish benefit, dose or safety in people using this blend.
cav2 1 use dependent block
A Europe PMC abstract reports that gamma-eudesmol produced both tonic block and use-dependent inhibition of CaV2.1 channel activity in an electrophysiology model.
Measured: use-dependent calcium-channel inhibition
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No verified human clinical safety trial, isolated-constituent dermal limit, or public RIFM monograph specific to gamma-eudesmol was located in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
The accessible pharmacology literature shows measurable cell and ion-channel activity, which is useful mechanistically but means isolated gamma-eudesmol should not be treated as inert without dose-specific safety data.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Whole-oil safety guidance for blue cypress, carrot seed, or hinoki should not be treated as direct proof of isolated gamma-eudesmol safety.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
caspase mediated apoptosis signal
A 2013 cell study reported that gamma-eudesmol reduced proliferation of multiple tumor cell lines and induced loss of mitochondrial membrane potential plus caspase-3 activation in HepG2 cells, consistent with a caspase-mediated apoptosis signal in vitro.
This experimental finding does not establish benefit, dose or safety in people using this blend.
cav2 1 channel blockade signal
A pharmacology paper found alpha- and gamma-eudesmol to inhibit presynaptic CaV2.1 currents with a use-dependent blocking profile in Xenopus oocyte assays, indicating ion-channel modulation as another plausible preclinical mechanism.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- No human clinical studies specific to isolated gamma-eudesmol were located in the reviewed public sources.
- No authoritative constituent-specific dermal limit, sensitization review, or phototoxicity study was verified in this pass.
- Most accessible positive bioactivity evidence is preclinical and focused on tumor-cell or electrophysiology models rather than consumer-relevant human outcomes.
- No IFRA Standard exists for gamma-eudesmol, so no category-specific dermal maximum could be sourced; the previously recorded dermal_limit_pct:20 and sensitizing:true values were not corroborated by any primary source found in this pass and should be treated as unverified placeholders.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.